Twist Bioscience vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
Synthetic DNA manufacturing platform on silicon chips; $376M FY2025 revenue (+20% YoY). Supplies synthetic genes to 3,000+ customers across biotech, pharma, and AgBio.
About
Twist Bioscience was founded in 2013 in San Francisco by Emily Leproust, Bill Banyai, and Bill Peck, pioneering a silicon-based DNA synthesis platform that writes synthetic DNA at a fraction of the cost and error rate of conventional methods. By printing DNA on silicon wafers using a semiconductor-like process, Twist dramatically reduced the cost of synthetic genes from hundreds to single-digit dollars per gene, democratizing access to DNA writing for the life sciences.\n\nTwist serves over 3,000 customers across biopharmaceuticals, academic research, agriculture, and industrial biotechnology, offering synthetic genes, variant libraries, DNA data storage oligos, and antibody libraries for drug discovery. The company reported $376.6 million in FY2025 revenue, up 20% from $313 million in FY2024, driven by strong growth in its biopharma and drug discovery segments. Twist also operates a growing antibody drug discovery business, providing synthetic antibody libraries that power next-generation therapeutic discovery programs.\n\nTwist has a supply agreement with Ginkgo Bioworks for synthetic DNA to fuel Ginkgo's cell engineering platform, revised in 2025. The company is executing toward profitability, with improving gross margins as manufacturing scale increases. Its silicon-based DNA synthesis platform positions it as critical infrastructure for the emerging bioeconomy, synthetic biology, and DNA data storage industries.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Also Compare
Twist Bioscience vs
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.